Sheikh, Z;
Potter, E;
Li, Y;
Drysdale, SB;
Wildenbeest, JG;
Robinson, H;
McGinley, J;
Lin, G-L;
Öner, D;
Aerssens, J;
et al.
Sheikh, Z; Potter, E; Li, Y; Drysdale, SB; Wildenbeest, JG; Robinson, H; McGinley, J; Lin, G-L; Öner, D; Aerssens, J; Justicia-Grande, AJ; Martinón-Torres, F; Pollard, AJ; Bont, L; Nair, H
(2024)
External validation of the discriminative validity of the ReSVinet score & development of simplified ReSVinet scores in secondary care.
J Infect Dis, 229 (Supplement 1).
S18-S24.
ISSN 1537-6613
https://doi.org/10.1093/infdis/jiad388
SGUL Authors: Drysdale, Simon Bruce
Preview |
|
PDF
Accepted Version
Available under License ["licenses_description_publisher" not defined].
Download (426kB)
| Preview
|
Abstract
BACKGROUND: There is no consensus on how to best quantify disease severity in infants with respiratory syncytial virus (RSV) and/or bronchiolitis; this lack of a sufficiently validated score complicates the provision of clinical care and, the evaluation of trials of therapeutics and vaccines. The ReSVinet score appears to be one of the most promising; however it is too time-consuming to be incorporated into routine clinical care. We aimed to develop and externally validate simplified versions of this score. METHODS: Data were used from a multinational (Netherlands, Spain & United Kingdom) multicentre case-control observational study of infants with RSV to develop simplified versions of the ReSVinet by conducting a grid search to determine the best combination of equally weighted parameters to maximise for the discriminative ability of the scores across a range of outcomes (hospitalisation, intensive care unit admission, ventilation requirement). Subsequently discriminative validity of the score for a range of secondary care outcomes was externally validated by conducting a secondary analysis of data collected in infants with respiratory infection from tertiary hospitals in Rwanda and Colombia. RESULTS: Three candidate simplified scores were identified using the development dataset; they were excellent (area under the receiver-operator characteristic curve [AUROC] >0.9) in the development dataset at discriminating for a range of outcomes, and their performance was not statistically significantly different to the original ReSVinet score despite having fewer parameters. In the external validation datasets, the simplified scores were moderate-excellent (AUROC 0.7-1) across a range of outcomes. In all outcomes, except for in a single dataset at predicting admission to the high dependency unit, they performed at least as well as the original ReSVinet score. CONCLUSIONS: Three promising candidate simplified scores were developed; however further external validation work in larger datasets, ideally from resource-limited settings needs to be conducted before any recommendation regarding their use.
Item Type: |
Article
|
Additional Information: |
This is a pre-copyedited, author-produced version of an article accepted for publication in The Journal of Infectious Diseases following peer review. The version of record Zakariya Sheikh, Ellie Potter, You Li, Simon B Drysdale, Joanne G Wildenbeest, Hannah Robinson, Joseph McGinley, Gu-Lung Lin, Deniz Öner, Jeroen Aerssens, Antonio José Justicia-Grande, Federico Martinón-Torres, Andrew J Pollard, Louis Bont, Harish Nair, on behalf of the PROMISE Investigators, External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care, The Journal of Infectious Diseases, Volume 229, Issue Supplement_1, 15 March 2024, Pages S18–S24 is available online at: https://doi.org/10.1093/infdis/jiad388 |
Keywords: |
RSV, severity score, validity, 06 Biological Sciences, 11 Medical and Health Sciences, Microbiology |
SGUL Research Institute / Research Centre: |
Academic Structure > Infection and Immunity Research Institute (INII) |
Journal or Publication Title: |
J Infect Dis |
ISSN: |
1537-6613 |
Language: |
eng |
Dates: |
Date | Event |
---|
15 March 2024 | Published | 15 September 2023 | Published Online | 6 September 2023 | Accepted |
|
Publisher License: |
Publisher's own licence |
Projects: |
Project ID | Funder | Funder ID |
---|
101034339 | Innovative Medicines Initiative 2 Joint Undertaking | UNSPECIFIED |
|
PubMed ID: |
37712125 |
|
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/115782 |
Publisher's version: |
https://doi.org/10.1093/infdis/jiad388 |
Statistics
Item downloaded times since 12 Oct 2023.
Actions (login required)
|
Edit Item |